ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "DMARDs"

  • Abstract Number: 798 • 2013 ACR/ARHP Annual Meeting

    Targeting Ultrasound Remission In Early Rheumatoid Arthritis – Results Of The Taser Study

    James Dale1, Anne Stirling2, Iain B. McInnes1 and Duncan Porter3, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Gartnavel General Hospital, Glasgow, United Kingdom, 3Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom

    Background/Purpose: The TaSER study (NCT00920478) is an open label randomized clinical trial with blinded assessments of outcome. It was designed to test whether the efficacy…
  • Abstract Number: 2265 • 2013 ACR/ARHP Annual Meeting

    Switching From Immediate Release (IR) Prednisone To Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs)

    Rieke Alten1, Robert Holt2, Amy Grahn3, Patricia Rice4, Jeffery Kent2, Frank Buttgereit5 and Allan Gibofsky6, 1Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, 2Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, 3Clinical Development, Horizon Pharma, Inc, Deerfield, IL, 4Statistics, CliniRx Research, Naperville, IL, 5Charité - Universitätsmedizin Berlin, Berlin, Germany, 6Medicine and Public Health, Hospital for Special Surgery, New York, NY

    Background/Purpose:    A surge in nocturnal inflammatory cytokines causing morning stiffness (MS) is recognized as a therapeutic target in RA. MS has been underappreciated in…
  • Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting

    Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study

    Zaki AbouZahr1, Andrew Spiegelman2, Maria Cantu3 and Bernard Ng4, 1Baylor College of Medicine, Houston, TX, 2Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, 3Baylor College Of Medicine, Houston, TX, 4Michael E. DeBakey VA Medical Center, Houston, TX

    Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…
  • Abstract Number: 1913 • 2013 ACR/ARHP Annual Meeting

    Expectations RA Patients Have For Their Treatment – A Comparison Of Clinical Results For Biologic and Disease-Modifying Anti-Rheumatic Drug Treated Patients Using Multiple Medical Cohorts

    Tsukasa Matsubara1,2, Hiroaki Matsuno2, Tomomaro Izumihara2, Yuichi Takahashi2, Akira Sagawa2, Motohiro Oribe2, Eisuke Shono2, Kensuke Kume2, Masanori Adachi2, Yuichi Nishioka2, Nobumasa Miyake2, Keisuke Hashimoto2, Toshikaki Miyamoto2, Shigeto Kiyokawa2, Tomohiko Yoshida2, Syoichi Kondo2, Yoshiki Shiohira2, Takanori Azuma2, Yukio Sato2, Masaaki Yoshida2, Kenji Mannami2, Akihiko Nakamura2, Yasuhiko Hirabarashi2, Keiko Funahashi3 and James E. Middleton4, 1Department of Orthopedics, Matsubara Mayflower Hospital, Kato, Japan, 2Japanese Clinician's Biologic Research Group, Kobe, Japan, 3Department of Clinical Research, Matsubara Mayflower Hospital, Kato, Japan, 4Research Institute of Joint Diseases, Kobe, Japan

    Background/Purpose: Treat to Target (T2T) primary principal - “The treatment of rheumatoid arthritis must be based on a shared decision between patient and rheumatologist”. Japan…
  • Abstract Number: 480 • 2013 ACR/ARHP Annual Meeting

    Levels Of Circulating Mirnas Before and After 12 Months Therapy With Dmards In Patients With Early Rheumatoid Arthritis

    Mária Filková1, Borbala Aradi2, Ladislav Senolt3, Klara Prajzlerova4, Serena Vettori2, Herman F. Mann5, Jiri Vencovsky4, K. Pavelka6, Beat A. Michel7, Renate E Gay2, Steffen Gay2 and Astrid Jüngel2, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 2Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 4Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 6Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 7Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: The altered expression of cellular miRNAs in the immune and resident cells involved in the pathogenesis of rheumatoid arthritis (RA) has been shown to…
  • Abstract Number: 1843 • 2013 ACR/ARHP Annual Meeting

    Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment

    Edward Bernton1 and Valerie Lowe2, 1Protalex Inc., Summit, NJ, 2Washington Biotechnology, Inc., Baltimore, MD

    Background/Purpose: PRTX-100 is a highly-purified GMP staphylococcal protein A (SpA) that  is currently in Phase I trials in patients with active rheumatoid arthritis (RA).  SpA…
  • Abstract Number: 489 • 2013 ACR/ARHP Annual Meeting

    Combining Methotrexate To Etanercept Does Not Improve Its Retention Rate In Rheumatoid Arthritis Patients When Compared To Etanercept Monotherapy. A Report From The Rhumadata® Clinical Data Base and Registry

    Denis Choquette1, Louis Bessette2, Boulos Haraoui1, Diane Sauvageau3, Jean Pierre Pelletier1, Jean-Pierre Raynauld3, Edith Villeneuve3 and Louis Coupal1, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, 3Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada

    Background/Purpose: Etanercept (ETA) has demonstrated good retention in both mono and combination therapy in clinical trials of rheumatoid arthritis patients followed over short observation periods…
  • Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting

    Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial

    P.H.P. de Jong1, A.E.a.M. Weel2, J.J. Luime3, P.J. Barendregt2, A.H. Gerards4, P.A. van der Lubbe4, M.H. de Jager5, P.B. de Sonnaville6, D. van Zeben7, B.A. Grillet8 and J.M.W. Hazes3, 1Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 3Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 4Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, 5Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, 6Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 7Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 8Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and  maintained with less treatment…
  • Abstract Number: 475 • 2013 ACR/ARHP Annual Meeting

    Alteration Of Aortic Distensibility Within 6 Months Of Treatment In RA Patients: An Observational Comparison Of Infliximab and Synthetic Dmards

    Birgul Ay1, Dilek Keskin2, Goksal Keskin3 and Ayhan Dinc4, 1Internal Medicine, DYB Research and Training Hospital, Ankara, Turkey, 2Immunology, DYB Research and Training Hospital, Ankara, Turkey, 3Internal Medicine and Clinical Immunology, DYB Research and Training Hospital, Ankara, Turkey, 4Rheumatology, Patio Clinic, Ankara, Turkey

    Background/Purpose: The proximal aorta accounts for most of the global arterial stiffening and subsequent complications. Aortic stiffness can be demonstrated by changes in aortic dimensions…
  • Abstract Number: 1760 • 2013 ACR/ARHP Annual Meeting

    Relationships Between Driving Distance, Rheumatoid Arthritis Diagnosis, and Disease-Modifying Anti-Rheumatic Drug Receipt

    Jennifer M. Polinski1, M. Alan Brookhart2, John Z. Ayanian3, Jeffrey N. Katz4, Seo Young Kim5, Chris Tonner6, Edward H. Yelin7 and Daniel H. Solomon8,9, 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 2University of North Carolina, Chapel Hill, NC, 3Brigham and Women's Hospital, Boston, MA, 4Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, 5Division of Rheumatology; Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, 6Medicine, University of California, San Francisco, San Francisco, CA, 7Arthritis Research Group, University of California, San Francisco, San Francisco, CA, 8Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 9Division of Rheumatology, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are recommended for all patients with rheumatoid arthritis (RA). Some studies estimate that almost half of patients with RA do…
  • Abstract Number: 441 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs

    G. R. Burmester1, C Charles-Schoeman2, J. D. Isaacs3, T. Hendrikx4, K. Kwok5, S. H. Zwillich6 and R. Riese6, 1Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, 2University of California, Los Angeles, CA, 3Newcastle University, Newcastle-upon-Tyne, United Kingdom, 4Pfizer BV, Capelle aan den IJssel, Netherlands, 5Pfizer Inc, New York, NY, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis provides comparative safety data on the incidence…
  • Abstract Number: 1713 • 2013 ACR/ARHP Annual Meeting

    Disparity In Biologic Therapy In Ethnic Minorities With Rheumatoid Arthritis: Can It All Be Due To Lack Of Access To Drug?

    Gail S. Kerr1, Ted R. Mikuls2, Christopher J. Swearingen3, Chunqiao Luo4 and Yusuf Yazici5, 1Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, 4Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, 5Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: Ethnic disparities in the administration of DMARDs exist, but the impact of differing health care systems on access in ethnic minorities treated by rheumatologists,…
  • Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting

    Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy

    A. Dikranian1, K. Soma2, R. Riese2, D. Gruben2 and T. V. Jones3, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
  • Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting

    Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)

    P.H.P. de Jong1, J.M.W. Hazes2, K.H. Han3, A.M. Huisman4, D. van Zeben5, P.A. van der Lubbe6, A.H. Gerards6, B. van Schaeybroeck7, P.B. de Sonnaville8, M.V. Krugten9, J.J. Luime2 and A.E.A.M. Weel3, 1Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 3Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 4Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 5Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 6Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, 7Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, 8Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 9Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands

    Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…
  • Abstract Number: 443 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations

    S. B. Cohen1, Roy Fleischmann1, J. M. Kremer2, A. Koenig3, K. Kwok4, L. Wang5, C. a. Mebus5, R. Riese5 and T. Robinson3, 1Metroplex Clinical Research Center, Dallas, TX, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor approved in the US for the treatment of rheumatoid arthritis at 5 mg BID. Phase (P) 3…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology